Nektar's Novel Opioid Unanimously Rejected by US FDA Advisory Cmte.
But more data on abuse potential and efficacy could offer path for forward for oxycodegol even after the FDA product-specific advisory committee meeting for an opioid analgesic in more than a year goes very badly for the sponsor.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.